Igc Pharma, INC

IGC Pharma, Inc. announced that its CEO and CFO purchased company stock by canceling significant outstanding debts owed to them by the company.

IGC Pharma, Inc. has amended its Master Loan and Security Agreement with O-Bank Co., Ltd., extending the facility with a $12 million aggregate limit and a revised fee structure.

IGC Pharma has entered into two securities purchase agreements to raise $514,960 in aggregate principal through convertible promissory notes.

IGC Pharma, Inc. completed a registered direct offering, issuing 779,997 common shares at $0.30 each, raising approximately $234,000 for working capital and clinical development.

IGC Pharma, Inc. announced a change in its fiscal year-end from March 31 to December 31, effective December 31, 2025.

IGC Pharma, Inc. has officially increased its authorized common stock from 150 million to 600 million shares, effective December 12, 2025, following stockholder approval.

IGC Pharma reports Q1 2026 financial results, highlighting progress in its Phase 2 CALMA clinical trial for IGC-AD1 and ongoing AI platform development.

IGC Pharma reported progress in its Phase 2 Alzheimer's trial and AI platform development, alongside a significant increase in cash and a reduced net loss for the six-month period, despite declining revenue.

IGC Pharma reported a 33% reduction in net loss for Q1 2026, driven by increased revenue and operational efficiencies, while advancing its lead Alzheimer's drug candidate and AI diagnostic platform.

IGC Pharma's Q3 2025 report reveals ongoing clinical trials for Alzheimer's treatment and a focus on revenue growth in its Life Sciences segment.

IGC Pharma's Q2 2025 report highlights positive Phase 2 trial results for IGC-AD1, a potential treatment for agitation in Alzheimer's, alongside a financial update showing increased revenue and reduced operating losses.

IGC Pharma's Q1 2025 report details financial results and progress in clinical trials for their Alzheimer's drug candidates, including IGC-AD1.

IGC Pharma, Inc. has strategically realigned its operations to focus solely on Life Sciences, reporting a significant reduction in net losses and encouraging interim Phase 2 clinical trial results for its lead Alzheimer's drug candidate, IGC-AD1, despite a decrease in overall revenue and cash reserves.

IGC Pharma's lead drug, IGC-AD1, shows significant reduction in agitation for Alzheimer's patients in a Phase 2 trial, with a faster onset of action compared to traditional medications.

IGC Pharma CEO Mukunda Ram converted $601,148 of outstanding debt into 2,226,475 shares of common stock at $0.27 per share.

Claudia Grimaldi, a Director and Officer of IGC Pharma, Inc., acquired 2,048,378 shares of common stock in exchange for canceling $553,062 in outstanding indebtedness.

Director Richard Prins acquired 170,000 shares of IGC Pharma common stock through the vesting and exercise of restricted stock units.

CEO Ram Mukunda increased his stake in IGC Pharma through the exercise of restricted stock units and stock options.

Director James P. Moran acquired 130,000 shares of IGC Pharma common stock through the vesting of restricted stock units.

IGC Pharma Director and PFO Claudia Grimaldi acquired 238,462 shares of common stock through the exercise of RSUs and stock options.

IGC Pharma, Inc. announces its 2025 Annual Meeting to vote on director elections, auditor ratification, a 5 million share incentive plan, and a significant increase in authorized common stock.

IGC Pharma, Inc. announces its 2025 Annual Stockholders Meeting to vote on director elections, auditor ratification, a 5 million share incentive plan, and a significant increase in authorized common stock.

IGC Pharma, Inc. announces its 2024 Annual Meeting to be held on August 23, 2024, with shareholders voting on director elections, auditor ratification, and stock grant approval.

IGC Pharma's proxy statement outlines key proposals for the upcoming annual meeting, including the election of directors, ratification of auditors, and approval of a share grant plan.